VIRTUAL - Doctor in the House - Dr Lisa Carey on Advancement in the Treatment of Triple Negative Breast Cancer
5:00 PM - 6:30 PM
Advances in the Treatment of Triple Negative Breast Cancer
Session begins at 5:00 PM
Please register above in order to receive the link to join the program.
Session Description: Please join us for an exciting and informative session on recent advancements in the treatment of triple negative breast cancer, led by Lisa Carey MD who was recently ranked as one of the top 10 breast cancer experts in the US. She is well known worldwide for her breast cancer research and it is truly an honor to have her with us.
Lisa A. Carey, MD, FASCO
L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology, and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center.
Research and Clinical Interests
Dr. Carey's research interests focus on breast cancer, including examination of different subtypes of breast cancer, evaluation on new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy. Dr. Carey has worked extensively with scientists across Lineberger Comprehensive Cancer Center and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype.
Members of the UNC Breast Center have a long commitment to improving treatment of early (nonmetastatic) breast cancer, and have been early investigators in the use of neoadjuvant, or preoperative, chemotherapy for breast cancer. In part based upon work performed at UNC, we now know that women do just as well if their chemotherapy is given before surgery as after, however the chemotherapy-first approach means that they are more likely to save their breast. In addition, with preoperative therapy it is possible to tell if the drugs are working since the tumor is still measurable when the chemotherapy is given first. Part of Dr. Carey's clinical research program investigates new drugs and combination of drugs in preoperative therapy. As part of this neoadjuvant chemotherapy program, she is involved in several studies, including a multi-institutional trial sponsored by the National Cancer Institute, of genetic and molecular markers in breast cancer as predictors of response to chemotherapy, and she is the lead investigator of a national study of new drug combinations in HER2-positive breast cancer. Dr. Carey is also the principal investigator of a highly collaborative study examining genes that might interact with other genes or with the environment to impact on a woman's risk of developing breast cancer.
She serves in national leadership roles on the National Cancer Institute Breast Cancer Steering Committee and the NCI-sponsored Alliance Translational Science Executive Committee, and the Translational Breast Cancer Research Consortium Steering Committee. Dr. Carey was selected co-chair of the Alliance National Cooperative Group Breast Committee in 2016.
Always check CBF website for updates and complete list of dates*
NOTE: This session will be delivered online using Zoom. You can participate using your computer, smartphone, or tablet. There is no cost involved or software to load. All you need is the meeting link and password, which we will provide via email confirmation when you register above (using the button at the top of this session description). We suggest using the provided meeting link a few minutes prior to the start time of the session. If you don't receive a confirmation email from us within an hour of registering, please check your SPAM folder or email : firstname.lastname@example.org
Contact CBF for more details:
Pink House Disclaimer....
Programs at Carolina Breast Friends should not be used as a substitute for any treatment. Sessions are intended to provide community and general support for breast cancer survivors. They are not intended to diagnose, treat, cure or prevent any disease. Consult your doctor if you are in any way concerned about activities that are part of an offered program.